Detected ·
Fore Biotherapeutics
$67.4M—
Fore Biotherapeutics announced the closing of an upsized Series D-2 extension financing, raising $67.4M to support late-stage development of plixorafenib for BRAF V600E CNS tumors, with a planned regulatory submission in 2027.
- Website
- fore.bio
- Amount
- $67 400 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-05 00:05:39 UTC
- Signal ID
- 90018150-3084-41a6-b761-b929e129c33f
As the API returns it
{
"id": "90018150-3084-41a6-b761-b929e129c33f",
"created_at": "2026-08-05T00:05:39.687830Z",
"company_name": "Fore Biotherapeutics",
"company_website_url": "fore.bio",
"company_linkedin_url": "https://www.linkedin.com/company/forebiotherapeutics",
"event_type": "funding",
"funding_amount": 67400000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Fore Biotherapeutics announced the closing of an upsized Series D-2 extension financing, raising $67.4M to support late-stage development of plixorafenib for BRAF V600E CNS tumors, with a planned regulatory submission in 2027.*"
}